Search

Displaying results 3461 - 3470 of 10000 in total
  1. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

    Categories: Corticosteroids for Systemic Use
  2. Drug

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10296
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 6a individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTIONSynonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
  3. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. … Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

    Categories: Heterocyclic Compounds with 4 or More Rings
  4. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    PF-07304814 is a small molecule prodrug that targets the 3CL<sup>pro</sup> protease (M<sup>pro)</sup>, which is used by viruses like SARS-CoV-2 to assemble and multiply[L31718]. … on preprint servers[L31733, L31125].

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Cyd dengue virus serotype 1 live (attenuated) antigen

    go.drugbank.com/drugs/DB15521
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  6. Drug

    Cyd dengue virus serotype 2 live (attenuated) antigen

    go.drugbank.com/drugs/DB15522
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  7. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  8. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials. … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

  9. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia. … It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.

  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    of patients with idiopathic myelofibrosis or essential thrombocythemia. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index